Frontlight ResearchEarly access
Taking people in NetherlandsPhase 2
Tests tadalafil for motor symptoms in early Parkinson's disease
Tests daily tadalafil in adults with early Parkinson's disease not yet on drugs.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- TADalafil in early-stage Parkinson’s Disease (TAD-PD)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 2 Mar 2026
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional
- Record updated
- 5 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage Parkinson's disease who have never taken Parkinson's medicine. It tests daily tadalafil over two weeks.
- Age
- Older than 18 years
- Sex
- All sexes can join
- Disease stage
- Early-stage Parkinson's disease, with no limits in daily life that would need symptom treatment
- Earlier treatment
- No earlier medicine for Parkinson's disease
Main reasons for not taking part
- Taking PDE-inhibitors for erectile dysfunction
- Unstable heart or brain blood vessel disease
- Multisystem atrophy (MSA), mild cognitive impairment or dementia
- Kidney problems (eGFR below 80 ml/min) or liver problems
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Diagnosis of early-stage Parkinson’s disease, with no limitations in daily functioning that would necessitate symptomatic treatment
- No prior medication for Parkinson’s disease
- Normal blood pressure (between >90/60 mm Hg and <120/80 mm Hg)
- Age older than 18 years
- Informed consent and comply with the study protocol
- Understand the Dutch language
Who cannot take part
- Currently taking PDE-inhibitors for erectile dysfunction
- Concurrent nitrate, nitric oxide donors, guanylate cyclase, nicorandil, theophylline alpha-blocker, cytochrome P-450 3A4 (CYP3A4) inhibitor/inducer, or prostacyclin analog use
- Significant alcohol or drug abuse
- (unstable) Cardiovascular and cerebrovascular disease
- Unilateral blindness, hereditary retinal disorders, or increased risk of blindness
- Unilateral deafness or history of severe hearing loss dependent upon hearing aid(s)
- Mild cognitive impairment (MCI) or dementia
- Suspicion of or a known history of renal (eGFR level < 80 ml/min) or hepatic insufficiency
- Multisystem atrophy (MSA)
- Abnormal electrocardiogram (ECG)
- Orthostatic hypotension: a decrease in systolic blood pressure ≥ 20 mmHg, or a decrease in diastolic blood pressure ≥ 10 mmHg
- Immunocompromised
- Pregnancy and breastfeeding
- Legally incompetent adults
- Clinically significant penile deformity
Where in Netherlands
- Amsterdam UMC Research B.V.Amsterdam, NetherlandsTaking people
About the trial
What the trial wants to find out
To assess whether daily tadalafil improves motor symptoms in Parkinson-drug naïve patients with early-stage Parkinson’s disease over a two-week follow-up period
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Prospective, Open-Label, Single-Center Pilot Study on the Efficacy of Daily Tadalafil in Early-Stage Parkinson’s Disease
- Plain-language title
- Tests tadalafil for motor symptoms in early Parkinson's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 5 January 2026